Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
The trial investigates the safety and effectiveness of ruxolitinib cream in treating children with nonsegmental vitiligo, a condition causing loss of skin pigment. It is a Phase 3, randomized, double-blind study aimed at evaluating how well this topical treatment works in pediatric participants aged 2 to 11 years with limited body surface affected by vitiligo. Participants are randomly assigned to receive either ruxolitinib 1.5% cream or a matching vehicle cream, both applied twice daily as a thin film to the affected skin areas. The study measures improvements in facial and total body vitiligo using specific scoring indexes over 24 and 52 weeks. Participants must stop other vitiligo treatments during the trial and are monitored for safety throughout. Throughout the study, participants undergo assessments including evaluation of skin pigment improvement using Facial Vitiligo Area Scoring Index F-VASI and Total Body Vitiligo Area Scoring Index T-VASI. Safety is tracked by recording any adverse events up to 30 days after treatment. Pharmacokinetic tests measure drug concentration at multiple time points. The total study duration extends up to nearly four years, with ongoing follow-up to evaluate treatment effects and safety.
Actively Recruiting
Researchers are evaluating the efficacy and safety of SAR445399, a drug administered by injection, in adults with moderate to severe hidradenitis suppurativa. This multinational, randomized, double-blind, placebo-controlled Phase 2 study aims to compare two different doses of SAR445399 with a placebo to find the best dose for treating this condition. Participants will be randomly assigned to receive one of two SAR445399 dose regimens or a matching placebo. The treatment period lasts 32 weeks, including a 16-week initial double-blind phase followed by a 16-week treatment-blinded extension period. The total study duration for each participant is up to 46 weeks, with a total of 16 study visits scheduled throughout this time. During the study, participants will be monitored through various assessments including clinical response measures such as Hidradenitis Suppurativa Clinical Response HiSCR levels, severity scoring, skin pain ratings, quality of life questionnaires, laboratory tests, vital signs, and electrocardiograms. Researchers will also track drug concentrations and immune responses. Safety will be closely monitored throughout the study and extension period to evaluate any adverse events or significant changes in health.
Actively Recruiting
This clinical trial studies the effects of a new treatment called corneal crosslinking CXL for eye conditions where the cornea becomes thin, steep, and misshapen, causing blurry vision. The trial focuses on patients aged 8 years and older diagnosed with keratoconus, ectasia after LASIK or PRK, pellucid marginal degeneration, progressive ectasia after previous CXL, or forme fruste keratoconus. The main goal is to find out if CXL can slow or stop the progression of these corneal diseases and prevent vision loss. Participants will receive CXL treatment where riboflavin Vitamin B2 eye drops is applied to the eye, followed by exposure to ultraviolet A UVA light. Two groups will be compared one group receives UVA treatment for 18 minutes and the other for 24 minutes, both with 15-second off-on cycling. The treatment aims to strengthen the cornea and stop disease progression. During the 6-month study, participants will attend up to 7 office visits for eye and vision tests. Researchers will measure corneal curvature using Kmax with the Pentacam and corrected distance visual acuity CDVA to evaluate effectiveness. Secondary measures include uncorrected visual acuity UCVA and possibly changes in higher order aberrations HOA and coma if wavefront testing is done. Safety and treatment effects will be monitored throughout the study period.
Actively Recruiting
Researchers are studying an experimental treatment called corneal crosslinking CXL for people with Down syndrome who have corneal conditions where the cornea thins, steepens, and becomes misshapen, causing blurred vision. This treatment aims to strengthen the cornea and possibly prevent or slow vision loss. The study focuses on whether CXL can stop or slow this progression. Participants must be at least 8 years old and diagnosed with Down syndrome or similar cognitive or developmental conditions. The treatment involves applying riboflavin Vitamin B2 eye drops to the eye, followed by exposure to ultraviolet A UVA light for 20 minutes. This process is called Epi-ON corneal cross-linking and is performed during the study. Participants will receive this treatment and be monitored over a 6-month period. Participants will attend up to 7 in-office visits during the 6 months, where various eye and vision tests will be conducted. Researchers will measure corneal curvature and vision changes using tools like the Pentacam and visual acuity tests. They will also assess vision improvements with additional measures such as high order aberrations and coma. The study includes follow-up visits to track treatment effects and safety over time.
Actively Recruiting
Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating the effect of olpasiran compared to a placebo on the risk of coronary heart disease death, heart attack, or urgent coronary revascularization in people at risk for a first major cardiovascular event who have elevated lipoproteina levels. This phase 3 study focuses on participants aged 50 to 105 years with multiple cardiovascular risk factors or evidence of atherosclerosis. Participants will be randomly assigned to receive either subcutaneous injections of olpasiran or a placebo. The study is designed as a double-blind, placebo-controlled trial, meaning neither participants nor researchers know who receives the active drug or placebo. The treatment period spans up to approximately 6.2 years, during which participants receive regular injections and monitoring. Throughout the study, participants will be assessed for the time until coronary heart disease death, myocardial infarction, or urgent coronary revascularization occurs. Additional measurements include changes in lipoproteina levels and monitoring of cardiovascular events, strokes, and safety through adverse event tracking. Participants will have regular evaluations over the treatment duration, ensuring close follow-up until study completion.
Actively Recruiting
This research is a rollover study for participants who have previously taken part in specific Incyte-sponsored clinical trials involving the drug povorcitinib, aimed at treating Hidradenitis Suppurativa HS. The purpose is to continue evaluating the treatments safety and tolerability over an extended period, building on prior studies. Participants must have completed treatment in the original trials without major safety concerns and shown clinical benefits. Participants will continue to receive povorcitinib orally, following the same dosing schedule and options as in their original parent study. This ongoing treatment phase allows researchers to monitor long-term effects and gather extended safety data. The study is designed as a single-group phase 3b trial focused on treatment. Throughout the study, participants will be regularly monitored for treatment-emergent adverse events over approximately three years. Researchers will also assess specific clinical measures at each visit to evaluate treatment impact. Participants are expected to comply with study procedures, including avoiding pregnancy or fathering children as outlined. The total participation duration extends up to about three years, with regular visits to track safety and treatment outcomes.
Actively Recruiting
Researchers are evaluating sarilumab, given at two different doses, for treating adults aged 50 years and older with early polymyalgia rheumatica PMR. This randomized, double-blind, placebo-controlled Phase 3 study aims to compare the effectiveness of sarilumab plus a 52-week prednisone taper against placebo plus the same prednisone taper. The purpose is to assess whether sarilumab can improve sustained remission rates and to determine its safety and tolerability in this population. Participants are assigned to one of three groups placebo with prednisone taper, sarilumab 150 mg every two weeks with prednisone taper, or sarilumab 200 mg every two weeks with prednisone taper. The prednisone taper lasts 52 weeks. The study includes an initial screening visit, baseline and randomization visit with first drug administration, multiple treatment visits every two weeks from Week 2 to Week 44, an end of treatment visit at Week 52, and a final study visit at Week 58. During the study, participants will undergo regular assessments including monitoring for remission status, flare rates, and changes in PMR activity scores. Safety will be evaluated by tracking adverse events, laboratory values, and antibody formation against the drug throughout the study period up to Week 58. Participants may also complete quality of life questionnaires during the study. The total participation time spans approximately 58 weeks.
Actively Recruiting
This research aims to assess the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have severe alopecia areata, characterized by 50% or greater scalp hair loss. The study includes a double-blind, randomized, placebo-controlled treatment phase followed by an open-label extension. The goal is to better understand how well deuruxolitinib works and how safe it is for this age group with significant hair loss. Participants will be randomly assigned to receive either deuruxolitinib tablets or matching placebo tablets taken orally twice daily for 24 weeks during the initial treatment period. Following this, all participants will have the opportunity to receive deuruxolitinib for an additional 52 weeks in an open-label extension phase. This design allows comparison of the drug to placebo and longer-term evaluation of the drugs effects. Throughout the study, participants will have regular assessments of their hair loss using the Severity of Alopecia Tool SALT at multiple time points up to week 24 and beyond. Safety will be closely monitored by tracking side effects, vital signs, heart tests, lab results, and physical exams. Additional measurements include patient and clinician impressions of improvement, quality of life, and mental health assessments. The total study duration can extend up to 76 weeks of treatment plus safety follow-up to fully evaluate outcomes and tolerability.